Essential Medicines · LP-001
Oral rehydration salts Sachet powder
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-001Essential Medicines
- Generic identity
- Oral rehydration saltsSachet powder
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-001
- Generic identity
- Oral rehydration salts
- Presentation
- Sachet powder
- Catalogue strength
- WHO low-osmolarity sachet for 200 mL; WHO low-osmolarity sachet for 1 L
- Catalogue pack
- Sachet; carton 100 sachets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: oral rehydration salts.
- Dosage form: sachet powder.
- Catalogue wording lists low-osmolarity sachets intended for 200 mL and 1 L final volumes.
- General proposed pack: sachet; carton of 100 sachets.
Layer 02 · Unresolved product-specific fields
- Exact quantitative composition for each sachet.
- Evidence that the finished presentation conforms to a WHO formulation/specification.
- Strength-to-pack/SKU mapping, label preparation instructions, storage and shelf life.
- Registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | WHO low-osmolarity sachet for 200 mL | Sachet powder | Sachet | General carton-of-100 pack only; SKU mapping not supplied | Composition and exact preparation directions require controlled product documentation. |
| B | WHO low-osmolarity sachet for 1 L | Sachet powder | Sachet | General carton-of-100 pack only; SKU mapping not supplied | Composition and exact preparation directions require controlled product documentation. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Oral rehydration salts combine glucose and electrolytes to replace fluid and salts lost during diarrhoea. Their clinical value depends on preparing the intended formulation with the exact labeled water volume. This is rehydration therapy rather than an antibiotic or a medicine that simply stops bowel movements. The ingredient background here does not establish that a particular Luang Pharma sachet meets a WHO specification or holds a marketing authorization.
Clinical context and therapeutic role
Oral rehydration is a central part of diarrhoea care, together with assessment of dehydration and continued appropriate nutrition. A clinician must identify people who cannot drink adequately, have shock, or need intravenous treatment. Blood in stools, persistent vomiting, worsening weakness, or reduced consciousness require prompt assessment. In children, nutrition status and eligibility for complementary zinc treatment matter; a sachet does not replace evaluation of the underlying illness.
Selected safety context
Incorrect dilution can produce harmful electrolyte concentrations. Do not estimate the water volume or add extra sugar, salt, juice, or other medicines unless the approved instructions specifically direct this. Severe dehydration, inability to drink, or altered consciousness are emergency warning signs. People with serious kidney or heart disease may need an individualized fluid plan. Safe water and hygienic preparation are important because contaminated solution can worsen gastrointestinal illness.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes premeasured oral-rehydration powder sachets for different final water volumes. The powder composition and sachet-to-water relationship must be verified separately for each presentation. Mention of a WHO formula in the source catalogue does not independently demonstrate conformity of the finished product.
Check the labeled water volume and sachet integrity before preparation. Follow the exact directions using safe water and a clean vessel. The storage of unopened sachets and any limit on keeping prepared solution must be taken from the authorized product instructions.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
Professional review should verify the precise presentation, intended population and current local authorization, then ensure that symptom treatment does not delay diagnosis or urgent care. The supplied label remains the source for patient instructions.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Approved/controlled formula and quantitative composition.
Exact sachet specification and artwork/IFU or label.
Finished-product quality/conformity evidence if a WHO-formulation claim is to be made.
Registration/market-status and manufacturing-site evidence for the destination.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B06 checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| WHO: Oral rehydration salts — production of the new ORSArchived source classification: WHO technical reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling or evidence of equivalence. |
| WHO: Diarrhoeal diseaseArchived source classification: WHO clinical public-health guidance | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-001.
Professional enquiries
Request product-specific evidence for LP-001.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.